Injectafer Lawsuit: FDA Boxed Warning and Claim Basics

FDA added a boxed warning to Injectafer on September 1, 2026, and no federal Injectafer multidistrict litigation is listed.

Last updated November 16, 2026 By Erik Lawson, Senior Editor

Injectafer lawsuits allege inadequate warnings about severe low blood phosphate. At LawfareClaims.org, we read the Food and Drug Administration (FDA) notice alongside the Judicial Panel on Multidistrict Litigation (JPML) docket list to separate the reported safety risk from the status of litigation. According to FDA, symptomatic cases continued to be reported despite earlier label changes, and FDA added a boxed warning on September 1, 2026. No Injectafer multidistrict litigation (MDL) appears on the JPML list dated November 2, 2026. Whether a particular person has a claim requires a licensed attorney's review.

Find a Lawyer for Your ClaimFree case review, no obligation to hire.

What the Injectafer Lawsuits Allege and What FDA Found

Claimants and plaintiff law firms allege that warnings about severe low blood phosphate after Injectafer treatment were inadequate. That is an allegation about the warnings. It is not a court finding. The FDA notice and court-panel sources reviewed contain no ruling, verdict or settlement on an Injectafer claim.

According to FDA, Injectafer is a prescription iron replacement medicine given by intravenous infusion. FDA says the medicine was originally approved in 2013 to treat iron deficiency anemia. FDA describes its approved uses as including certain patients aged one year or older who cannot tolerate oral iron or do not respond fully to it. FDA also lists iron deficiency in adults with non-dialysis-dependent chronic kidney disease and iron deficiency in certain adults with heart failure.

According to FDA, symptomatic hypophosphatemia means low phosphate in the blood that produces symptoms. FDA says the effects can depend on how severe the phosphate loss is and how long it lasts. Its September 2026 notice describes outcomes that included hospitalization, phosphate replacement over weeks to months, and regular follow-up visits. FDA also says chronic severe hypophosphatemia may lead to osteomalacia, or bone softening, and fractures.

FDA says its 2026 assessment drew on its Adverse Event Reporting System (FAERS), published literature reports and its Sentinel System. According to FDA, reports of symptomatic hypophosphatemia continued after the earlier warning and monitoring changes. FDA says the FAERS case series included reports after both single and multiple infusions.

According to FDA, the September 2026 boxed warning describes the risk. It calls for phosphate monitoring in patients at risk and in anyone receiving a repeat course within three months of the prior course. A label change documents FDA's safety action. It does not decide whether an earlier warning was legally inadequate, whether a particular infusion caused an injury, or whether any claimant can recover money.

FDA Label History for Injectafer

According to FDA, the September 2026 boxed warning followed several earlier steps concerning low phosphate. The dates and changes below come from FDA's Injectafer safety communication.

Date FDA step What it added
2019 FDA determined that ferric carboxymaltose injection can cause serious symptomatic hypophosphatemia. FDA identified a serious risk of low blood phosphate with symptoms.
February 2020 FDA approved labeling revisions. According to FDA, the revisions added a warning about symptomatic hypophosphatemia, along with other changes.
May 2023 FDA revised the warning. FDA says it added monitoring recommendations for patients at risk and for anyone receiving a repeat course within three months. FDA also added osteomalacia and fractures as possible long-term complications and inflammatory bowel disease as a possible risk factor.
2025 FDA revised the warning again. According to FDA, the revision added further risk factors for hypophosphatemia.
2026 assessment FDA reviewed adverse-event reports, literature and Sentinel data. FDA found that symptomatic hypophosphatemia continued to be reported despite the earlier label changes.
September 1, 2026 FDA approved a boxed warning. FDA says the warning describes symptomatic hypophosphatemia and highlights a warning already present in the labeling.

According to FDA, Sentinel data indicate that serum phosphate testing occurs in fewer than 20% of ferric carboxymaltose administration episodes. FDA says appropriate phosphate monitoring and early intervention can prevent this serious reaction or reduce its severity. The testing figure describes administration episodes in FDA's data. It does not establish what happened during any particular person's care.

The sequence also matters for an attorney's review. Someone with records from a particular infusion can identify which label changes came before that date. A later boxed warning alone cannot establish what a patient or health care provider was told earlier, or resolve whether the medicine caused a diagnosed injury.

What Symptoms FDA Tells Patients to Report

According to FDA, patients should immediately report new or worsening muscle weakness or pain, fatigue, bone and joint pain, or confusion to their health care provider. FDA says some of these symptoms may resemble those of iron deficiency anemia. A symptom that feels familiar is therefore worth describing with its start date and any available phosphate test results when you speak to your provider.

FDA also describes tremors, seizures and cardiac arrhythmias among possible clinical manifestations of hypophosphatemia. Its separate patient-facing list names muscle weakness or pain, fatigue, bone and joint pain, and confusion as symptoms to report. FDA says severity and duration affect how low phosphate may appear clinically. The presence of a symptom alone does not establish its cause.

According to FDA, its guidance to health care providers includes checking phosphate before certain repeat courses and correcting pre-existing low phosphate. FDA also tells providers to monitor patients at risk, treat low phosphate as medically indicated, and consider permanent discontinuation in severe or persistent cases. FDA gave those instructions to providers. They are not treatment steps for readers. Talk to your own health care provider about symptoms, test results and care decisions.

FDA also urges patients and health care providers to report suspected side effects through FDA MedWatch. A MedWatch report tells FDA about a suspected reaction. It is separate from asking a licensed attorney to assess a possible injury claim.

Who May Have a Claim

A lawyer assessing a possible Injectafer claim would need to review the person's infusion records, diagnosed injury, symptom and laboratory timeline, and applicable state filing deadline. No source reviewed establishes that anyone qualifies. FDA's safety finding describes a drug risk across reports. An individual claim requires an examination of an individual's records.

Start with proof of the infusion. Check clinic or hospital records for the medicine and the infusion date. Dates help an attorney compare the infusion with phosphate test results, symptom reports and the label history. If the records show more than one infusion, keep the dates for each one rather than treating the course as a single event.

A diagnosis and test results matter for a different reason. Muscle pain or fatigue can prompt a conversation with a health care provider, but the symptom alone does not identify its cause. According to FDA, some symptoms of low phosphate can mimic iron deficiency anemia. An attorney can review the medical record for a diagnosed injury and ask how the documented findings relate to the infusion timeline.

Timing also affects the legal question. A state statute of limitation sets the deadline to file an injury suit, and the deadline varies by state. The clock can depend on when an injury was connected, or should have been connected, to a drug. Do not assume that the date of FDA's boxed warning starts the clock for an individual case. Ask a licensed attorney about the deadline that may apply to your facts.

Someone seeking treatment or dosing advice should talk to a health care provider instead. It also cannot provide an Injectafer settlement amount, because the sources reviewed contain no settlement. For a comparison with a drug that was withdrawn from the market, see how a drug-withdrawal claim differs. FDA's Injectafer notice describes a labeling change and does not say Injectafer was withdrawn.

Litigation Status: No Federal MDL on the JPML List

As of the JPML Pending MDL report dated November 2, 2026, no Injectafer or ferric carboxymaltose MDL is listed among active transferred MDLs. The Eastern District of Pennsylvania court's MDL page, reviewed on November 16, 2026, also lists no Injectafer MDL. There is no centralized federal Injectafer proceeding identified in those lists to join.

An MDL brings individual federal cases before one judge for shared pretrial work. Each plaintiff keeps an individual case. The related guide explains what an MDL does in a mass tort. An MDL listing would describe coordination. It would not decide that every person treated with the medicine has a claim.

The JPML report tracks MDLs. It does not track every lawsuit. It does not establish how many individual or state-court Injectafer cases exist, where they stand, or whether a particular person has filed one. The number and status of those cases remain unknown from the sources reviewed here. The same sources contain no court ruling, verdict or settlement on Injectafer claims.

For a current federal coordination status, use the JPML court site to check court dockets rather than relying on a description of an Injectafer MDL elsewhere. Ask a licensed attorney to review the dockets relevant to your case.

How to Start: Records, Deadlines and Talking to an Attorney

An Injectafer inquiry starts with records that identify the infusion, the injury and the dates connecting them. Gather what you have. Missing records are a question to raise with the clinic, hospital or attorney. Do not wait to ask about a filing deadline while trying to assemble a perfect packet.

  1. Gather infusion records. Write down each infusion date and the clinic or hospital where it took place. Ask for records that identify the medicine administered.
  2. Gather laboratory results and diagnoses. Include phosphate results if available, along with records of any diagnosed injury. Keep the date of each result so a health care provider or attorney can see the sequence.
  3. Write a dated symptom timeline. Note when symptoms began, what you reported to a health care provider, and when any diagnosis or follow-up occurred. Keep the account tied to what you remember and what the records show.
  4. Flag the filing deadline. State limitation periods vary. The relevant clock can depend on when an injury was, or should have been, connected to a drug. Ask an attorney which state's deadline may govern rather than choosing one from a general description online.
  5. Talk to a licensed attorney. Bring the records and timeline. Ask what additional documents are needed, whether the available evidence supports an individual claim, and what filing deadline applies.

The guide on how to file a lawsuit explains the broader filing process. If you need someone to review the records and deadline, use the lawyer directory to look for a licensed attorney. Take your infusion dates, phosphate results and symptom timeline to that conversation, and ask whether an Injectafer lawsuit fits your records.

Our Takeaway on the Injectafer Lawsuit

Injectafer claims allege inadequate warnings about severe low blood phosphate. According to FDA, symptomatic cases kept being reported despite earlier label changes, and FDA approved a boxed warning on September 1, 2026. FDA's findings support taking the risk seriously. They do not rule on any lawsuit. The JPML list dated November 2, 2026 shows no active transferred Injectafer MDL. A possible claim therefore needs individual review of the medical records and state deadline by a licensed attorney. A JPML transfer order or court docket showing coordinated litigation, a published settlement, or another FDA label action would change the status described here.

Injectafer Lawsuit FAQs

Is there an Injectafer lawsuit?

Claimants and plaintiff law firms describe Injectafer claims alleging inadequate warnings about severe low blood phosphate. The sources reviewed here do not establish the number or status of individual or state-court cases, and they contain no ruling or settlement on those claims. A licensed attorney must assess whether a particular person has a viable claim.

Is there an Injectafer MDL?

No Injectafer or ferric carboxymaltose MDL appears among active transferred MDLs in the JPML report dated November 2, 2026. That report does not track individual or state-court cases. A federal MDL is a way to coordinate shared pretrial work in individual cases, rather than a finding that the claims will succeed.

What is hypophosphatemia according to FDA?

According to FDA, hypophosphatemia means low levels of phosphate in the blood. FDA says its clinical effects depend on severity and duration. FDA lists new or worsening muscle weakness or pain, fatigue, bone and joint pain, and confusion among the symptoms patients should immediately report to their health care provider.

Was Injectafer recalled or taken off the market?

FDA's September 1, 2026 notice describes adding a boxed warning to Injectafer labeling and says nothing about a recall or withdrawal. The notice should not be read as an announcement that Injectafer was taken off the market.

What is a boxed warning?

According to FDA, a boxed warning is the agency's most prominent safety warning. FDA says the Injectafer boxed warning describes the risk of symptomatic hypophosphatemia and highlights a warning already present in the labeling. A boxed warning is a labeling action. It is not a court decision about a claimant's injury.

How do I report Injectafer side effects?

FDA urges patients and health care providers to report suspected side effects through FDA MedWatch. According to FDA, patients should immediately report new or worsening symptoms on its patient list to their health care provider. Reporting a suspected side effect and asking an attorney to review a claim are separate steps.

Can I join an Injectafer class action?

The JPML report tracks MDLs and does not track class actions, so it cannot establish whether an Injectafer class action exists. It also lists no active transferred federal Injectafer MDL as of November 2, 2026. A mass tort or MDL coordinates work on individual injury cases. It does not mean every person can join one case. Take your infusion and injury records to a licensed attorney and ask whether an individual Injectafer claim is available within your state's filing deadline.

Find a Lawyer for Your Claim

Not sure where you stand?

Check your eligibility in under 2 minutes — free, private, and no commitment required.